These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 24117687)
41. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era. Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029 [TBL] [Abstract][Full Text] [Related]
42. Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. Chen Z; Du Z; Chen J; Chen Z; Bao Y; Tang F Med Oncol; 2011 Mar; 28(1):241-8. PubMed ID: 20165991 [TBL] [Abstract][Full Text] [Related]
43. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H; Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442 [TBL] [Abstract][Full Text] [Related]
44. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N; Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214 [TBL] [Abstract][Full Text] [Related]
45. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946 [TBL] [Abstract][Full Text] [Related]
46. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848 [TBL] [Abstract][Full Text] [Related]
47. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115 [TBL] [Abstract][Full Text] [Related]
48. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569 [TBL] [Abstract][Full Text] [Related]
49. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200 [TBL] [Abstract][Full Text] [Related]
50. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Hasselblom S; Stenson M; Werlenius O; Sender M; Lewerin C; Hansson U; Nilsson-Ehle H; Andersson PO Leuk Lymphoma; 2012 Mar; 53(3):394-9. PubMed ID: 21864039 [TBL] [Abstract][Full Text] [Related]
51. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944 [TBL] [Abstract][Full Text] [Related]
52. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Benesova K; Forsterova K; Votavova H; Campr V; Stritesky J; Velenska Z; Prochazka B; Pytlik R; Trneny M Neoplasma; 2013; 60(1):68-73. PubMed ID: 23067219 [TBL] [Abstract][Full Text] [Related]
53. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Jais JP; Haioun C; Molina TJ; Rickman DS; de Reynies A; Berger F; Gisselbrecht C; Brière J; Reyes F; Gaulard P; Feugier P; Labouyrie E; Tilly H; Bastard C; Coiffier B; Salles G; Leroy K; Leukemia; 2008 Oct; 22(10):1917-24. PubMed ID: 18615101 [TBL] [Abstract][Full Text] [Related]
54. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685 [TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Winter JN; Weller EA; Horning SJ; Krajewska M; Variakojis D; Habermann TM; Fisher RI; Kurtin PJ; Macon WR; Chhanabhai M; Felgar RE; Hsi ED; Medeiros LJ; Weick JK; Reed JC; Gascoyne RD Blood; 2006 Jun; 107(11):4207-13. PubMed ID: 16449523 [TBL] [Abstract][Full Text] [Related]
56. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Ott G; Ziepert M; Klapper W; Horn H; Szczepanowski M; Bernd HW; Thorns C; Feller AC; Lenze D; Hummel M; Stein H; Müller-Hermelink HK; Frank M; Hansmann ML; Barth TF; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Loeffler M; Rosenwald A Blood; 2010 Dec; 116(23):4916-25. PubMed ID: 20736456 [TBL] [Abstract][Full Text] [Related]
57. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349 [TBL] [Abstract][Full Text] [Related]
58. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633 [TBL] [Abstract][Full Text] [Related]
59. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy. Tumati V; Trivedi L; Li HC; Patel P; Scaglioni PP; Vusirikala M; Sadeghi N; Rizvi S; Chen W; Wachsmann J; Collins R; Desai NB Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1126-1132. PubMed ID: 29722657 [TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Lu TX; Gong QX; Wang L; Fan L; Zhang XY; Chen YY; Wang Z; Xu W; Zhang ZH; Li JY Int J Clin Exp Pathol; 2015; 8(1):275-86. PubMed ID: 25755714 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]